Propel previously shared a billing code with Intersect ENT’s Sinuva implant, the release said. The new approval establishes a separate code for Propel and updates Sinuva’s J-Code to J7402.
Propel products are the first and only bioabsorbable steroid-releasing sinus implants approved by the FDA to maintain patency and locally deliver steroids to adults after sinus surgery, the release said.
More articles on healthcare:
Ophthalmologist convicted of $73M billing fraud has 17-year sentence commuted by Trump
What hospitals posting rates online means for ASCs
Optum reports revenue of $35.9B in Q4, $136.3B in 2020 — 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
